Seres Therapeutics’ highly anticipated clinical trial in ulcerative colitis failed to meet its primary endpoint, the company announced Thursday. Seres, which is focused on microbiome therapeutics, is also shutting down two ongoing open label and maintenance studies of the therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.